Budget impact analysis of the freestyle libre flash continuous glucose monitoring system® in patients with diabetes mellitus type 1 in Chile

Alfredo Palacios; Federico Rodriguez Cairoli; Dario Balan; Carlos Balmaceda; Federico Augustovski; Andres Pichon-Riviere; Ariel Bardach

doi:10.1080/14737167.2023.2171989

Budget impact analysis of the freestyle libre flash continuous glucose monitoring system® in patients with diabetes mellitus type 1 in Chile

Alfredo Palacios, Federico Rodriguez Cairoli, Dario Balan, Carlos Balmaceda, Federico Augustovski, Andres Pichon-Riviere, Ariel Bardach

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To estimate the budget impact of covering the FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for type 1 Diabetes Mellitus patients (T1DM), compared to self-monitoring of blood glucose (SMBG), from the perspective of public and private third-party payers in Chile.

METHODS: A budget impact model was developed to estimate the cost difference between SMBG and FSL over five years. Two FSL coverage schemes were assessed. Input parameters were retrieved from the literature review and complemented by expert opinion. Healthcare costs were estimated by a micro-costing approach and reported in USD.

RESULTS: For a public sector third-party payer, incorporating FSL implied a cost increase up to USD 0.013 per member per month (PMPM) for the fifth year under the broad coverage scheme and a net saving of 0.0001 PMPM (all years) under the restricted coverage scheme. From a private sector third-party payer, incorporating FSL implied savings up to USD 0.028 PMPM (fifth year) for the broad coverage scheme and up to USD 0.012 PMPM (fifth year) for the restricted scheme.

CONCLUSION: Incorporating the FSL for T1DM patients was associated with a marginal incremental cost for the public sector third-party payer and cost savings in Chile's private healthcare sector.

Original language	English
Number of pages	11
Journal	Expert Review of Pharmacoeconomics & Outcomes Research
Early online date	31 Jan 2023
DOIs	https://doi.org/10.1080/14737167.2023.2171989
Publication status	E-pub ahead of print - 31 Jan 2023

Access to Document

10.1080/14737167.2023.2171989

BIA_FSL_Chile
This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details
Accepted author manuscript, 2.38 MB

Cite this

Palacios, A., Rodriguez Cairoli, F., Balan, D., Balmaceda, C., Augustovski, F., Pichon-Riviere, A., & Bardach, A. (2023). Budget impact analysis of the freestyle libre flash continuous glucose monitoring system® in patients with diabetes mellitus type 1 in Chile. Expert Review of Pharmacoeconomics & Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2023.2171989

@article{34e1a2cfc8644b12a59f34335d47e8da,

title = "Budget impact analysis of the freestyle libre flash continuous glucose monitoring system{\textregistered} in patients with diabetes mellitus type 1 in Chile",

abstract = "OBJECTIVE: To estimate the budget impact of covering the FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for type 1 Diabetes Mellitus patients (T1DM), compared to self-monitoring of blood glucose (SMBG), from the perspective of public and private third-party payers in Chile.METHODS: A budget impact model was developed to estimate the cost difference between SMBG and FSL over five years. Two FSL coverage schemes were assessed. Input parameters were retrieved from the literature review and complemented by expert opinion. Healthcare costs were estimated by a micro-costing approach and reported in USD.RESULTS: For a public sector third-party payer, incorporating FSL implied a cost increase up to USD 0.013 per member per month (PMPM) for the fifth year under the broad coverage scheme and a net saving of 0.0001 PMPM (all years) under the restricted coverage scheme. From a private sector third-party payer, incorporating FSL implied savings up to USD 0.028 PMPM (fifth year) for the broad coverage scheme and up to USD 0.012 PMPM (fifth year) for the restricted scheme.CONCLUSION: Incorporating the FSL for T1DM patients was associated with a marginal incremental cost for the public sector third-party payer and cost savings in Chile's private healthcare sector.",

author = "Alfredo Palacios and {Rodriguez Cairoli}, Federico and Dario Balan and Carlos Balmaceda and Federico Augustovski and Andres Pichon-Riviere and Ariel Bardach",

year = "2023",

month = jan,

day = "31",

doi = "10.1080/14737167.2023.2171989",

language = "English",

journal = "Expert Review of Pharmacoeconomics & Outcomes Research",

issn = "1473-7167",

publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Budget impact analysis of the freestyle libre flash continuous glucose monitoring system® in patients with diabetes mellitus type 1 in Chile

AU - Palacios, Alfredo

AU - Rodriguez Cairoli, Federico

AU - Balan, Dario

AU - Balmaceda, Carlos

AU - Augustovski, Federico

AU - Pichon-Riviere, Andres

AU - Bardach, Ariel

PY - 2023/1/31

Y1 - 2023/1/31

N2 - OBJECTIVE: To estimate the budget impact of covering the FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for type 1 Diabetes Mellitus patients (T1DM), compared to self-monitoring of blood glucose (SMBG), from the perspective of public and private third-party payers in Chile.METHODS: A budget impact model was developed to estimate the cost difference between SMBG and FSL over five years. Two FSL coverage schemes were assessed. Input parameters were retrieved from the literature review and complemented by expert opinion. Healthcare costs were estimated by a micro-costing approach and reported in USD.RESULTS: For a public sector third-party payer, incorporating FSL implied a cost increase up to USD 0.013 per member per month (PMPM) for the fifth year under the broad coverage scheme and a net saving of 0.0001 PMPM (all years) under the restricted coverage scheme. From a private sector third-party payer, incorporating FSL implied savings up to USD 0.028 PMPM (fifth year) for the broad coverage scheme and up to USD 0.012 PMPM (fifth year) for the restricted scheme.CONCLUSION: Incorporating the FSL for T1DM patients was associated with a marginal incremental cost for the public sector third-party payer and cost savings in Chile's private healthcare sector.

AB - OBJECTIVE: To estimate the budget impact of covering the FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for type 1 Diabetes Mellitus patients (T1DM), compared to self-monitoring of blood glucose (SMBG), from the perspective of public and private third-party payers in Chile.METHODS: A budget impact model was developed to estimate the cost difference between SMBG and FSL over five years. Two FSL coverage schemes were assessed. Input parameters were retrieved from the literature review and complemented by expert opinion. Healthcare costs were estimated by a micro-costing approach and reported in USD.RESULTS: For a public sector third-party payer, incorporating FSL implied a cost increase up to USD 0.013 per member per month (PMPM) for the fifth year under the broad coverage scheme and a net saving of 0.0001 PMPM (all years) under the restricted coverage scheme. From a private sector third-party payer, incorporating FSL implied savings up to USD 0.028 PMPM (fifth year) for the broad coverage scheme and up to USD 0.012 PMPM (fifth year) for the restricted scheme.CONCLUSION: Incorporating the FSL for T1DM patients was associated with a marginal incremental cost for the public sector third-party payer and cost savings in Chile's private healthcare sector.

U2 - 10.1080/14737167.2023.2171989

DO - 10.1080/14737167.2023.2171989

M3 - Article

C2 - 36701814

SN - 1473-7167

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

ER -